MX2014000113A - Compuestos para tratar neuropatias perifericas y otros desordenes neurodegenerativos. - Google Patents

Compuestos para tratar neuropatias perifericas y otros desordenes neurodegenerativos.

Info

Publication number
MX2014000113A
MX2014000113A MX2014000113A MX2014000113A MX2014000113A MX 2014000113 A MX2014000113 A MX 2014000113A MX 2014000113 A MX2014000113 A MX 2014000113A MX 2014000113 A MX2014000113 A MX 2014000113A MX 2014000113 A MX2014000113 A MX 2014000113A
Authority
MX
Mexico
Prior art keywords
compounds
neurodegenerative disorders
peripheral neuropathies
treating peripheral
disease
Prior art date
Application number
MX2014000113A
Other languages
English (en)
Inventor
Ahmet Hoke
Weiran Chen
Jing Zhu
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of MX2014000113A publication Critical patent/MX2014000113A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Abstract

Se proporciona compuesto y métodos para el tratamiento o la prevención de una enfermedad, trastorno o afección neurodegenerativa asociada con la actividad general de hsp90 pero no con la actividad de ATPasa de hsp90, incluyendo neuropatía, tal como neuropatía periférica causada por quimioterapia o diabetes, trastornos del sistema nervioso central, tal como enfermedad de Alzheimer y enfermedad de parkinson, y enfermedades neuromotoras tales como esclerosis lateral amiotrófica (ALS), en un sujeto.
MX2014000113A 2011-06-21 2012-06-21 Compuestos para tratar neuropatias perifericas y otros desordenes neurodegenerativos. MX2014000113A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161499242P 2011-06-21 2011-06-21
US201161499921P 2011-06-22 2011-06-22
PCT/US2012/043475 WO2012177831A2 (en) 2011-06-21 2012-06-21 Compounds for treating peripheral neuropathies and other neurodegenerative disorders

Publications (1)

Publication Number Publication Date
MX2014000113A true MX2014000113A (es) 2015-04-13

Family

ID=47423197

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014000113A MX2014000113A (es) 2011-06-21 2012-06-21 Compuestos para tratar neuropatias perifericas y otros desordenes neurodegenerativos.

Country Status (7)

Country Link
US (1) US9527817B2 (es)
EP (1) EP2723339A4 (es)
CN (1) CN103702669A (es)
AU (1) AU2012272924A1 (es)
CA (1) CA2840003A1 (es)
MX (1) MX2014000113A (es)
WO (1) WO2012177831A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104569398B (zh) * 2013-10-22 2016-06-22 北京勤邦生物技术有限公司 检测乙氧基喹啉的酶联免疫试剂盒及其应用
PT3377476T (pt) * 2015-11-16 2022-12-29 Ptc Therapeutics Inc Análogos enriquecidos com isótopo de hidrogénio de compostos de ácido 1,2,4-oxadiazole benzoico, composições e suas utilizações
CN107779436A (zh) * 2017-10-27 2018-03-09 南京中医药大学 化疗所致周围神经病变细胞模型构建及其检测方法
US11234947B2 (en) * 2020-06-30 2022-02-01 Imperial College Innovations Limited Treatment of peripheral neuropathy induced by cancer chemotherapy
WO2022265960A1 (en) * 2021-06-13 2022-12-22 Daya Drug Discoveries, Inc. Prevention and treatment of neuronal damage with pyridoindolobenz[b, d] azepine compositions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3952023A (en) * 1972-12-16 1976-04-20 Nippon Oil Company Ltd. Method for preparing adduct of butadiene polymer or copolymer and α, β-ethylenically unsaturated dicarboxylic acid compound
US4196113A (en) 1973-11-01 1980-04-01 Nippon Oil Co., Ltd. Water-soluble coating composition
US6746678B1 (en) * 1991-02-22 2004-06-08 Howard K. Shapiro Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments
US6335157B1 (en) 1999-05-07 2002-01-01 The European Molecular Biology Laboratory Method based on localization of Hsp90 to the centrosome
US20070078144A1 (en) * 2003-01-29 2007-04-05 Stockwell Brent R Agents for treating neurodegenerative diseases
CN1897972A (zh) * 2003-12-22 2007-01-17 爱尔康公司 用于治疗青光眼性视网膜病和视神经病的活性剂
US20090179638A1 (en) 2006-02-01 2009-07-16 Aegera Therapeutics Inc. Assay for identifying inhibitors of neuronal apoptotic pathways
US7960353B2 (en) 2007-05-10 2011-06-14 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
EP2226632B1 (en) 2007-12-28 2014-02-12 Takeda Pharmaceutical Company Limited Method for screening of cell-protecting agent

Also Published As

Publication number Publication date
US9527817B2 (en) 2016-12-27
CA2840003A1 (en) 2012-12-27
CN103702669A (zh) 2014-04-02
WO2012177831A3 (en) 2013-04-11
EP2723339A2 (en) 2014-04-30
WO2012177831A2 (en) 2012-12-27
US20140303203A1 (en) 2014-10-09
AU2012272924A1 (en) 2014-01-16
EP2723339A4 (en) 2015-02-25

Similar Documents

Publication Publication Date Title
MX2014000113A (es) Compuestos para tratar neuropatias perifericas y otros desordenes neurodegenerativos.
MX2017014443A (es) Adeno-asociado para administracion terapeutica al sistema nervioso central.
MX2013006056A (es) Metodos para diagnosticar y tratar trastornos relacionados con la longitud del ojo.
MX354662B (es) Anticuerpos fosfoespecificos que reconocen la tau.
WO2014150817A3 (en) Method and system to predict response to treatments for mental disorders
MX2008009947A (es) Composiciones farmaceuticas que comprenden dextrometorfano y quinidina para el tratamiento de depresion, ansiedad y trastornos neurodegenerativos.
EP3498729A3 (en) Therapeutic targets for alzheimer's disease
AU2012205878A8 (en) miRNA for treating diseases and conditions associated with neo-angiogenesis
WO2014037416A3 (en) Compositions for treating parkinson's disease
MX2013008067A (es) Metodos y productos de farmaco para tratar enfermedad de alzheimer.
EA033420B1 (ru) Производные индолин-2-она или пирролопиридин-2-она, обладающие антипсихотической активностью
WO2014186599A3 (en) Anti-complement factor c1s antibodies and uses thereof
WO2013033037A3 (en) Novel antiprion compounds
EA201991375A1 (ru) Бицикло[1.1.1]пентановые ингибиторы киназы, содержащей домен с двумя лейциновыми "застежками-молниями" (dlk), для лечения заболевания
CA2851761C (en) Method of diagnosis, prognostic or treatment of neurodegenerative diseases
EP2542085A4 (en) COMPOUNDS FOR THE TREATMENT OF NEURODEEGENERATIVE DISORDER
MX2019013524A (es) Composiciones para tratar enfermedades neurodegenerativas.
ATE382101T1 (de) Einen transkriptionsfaktor kodierendes humanes prädispositionsgen für autismus sowie dessen verwendungen
WO2006087634A3 (en) Uses of human autism susceptibility gene encoding a kinase
WO2008057609A8 (en) Methods of treating neuronal disorders using mntf peptides and analogs thereof
WO2012103282A3 (en) Methods and compositions for treating alzheimer's disease
RU2014153894A (ru) Способ предупреждения неврологических заболеваний
SA515360200B1 (ar) محاكيات عامل نمو خلية كبدية كعوامل علاجية
WO2012068553A3 (en) Methods of diagnosing and treating neurodegenerative diseases
WO2011163607A3 (en) Olfactory receptor copy number association with age at onset of alzheimer's disease